Ocular Therapeutix, spurred by positive results from a Phase I trial, launches a Phase II clinical study of a drug-releasing tear duct plug for treatment of ocular hypertension and glaucoma.

Ocular Therapeutix launched a Phase II trial of its punctum plugs, a possible eye-drop killer for patients with glaucoma or ocular hypertension.

The company's travoprost-releasing punctum plug, designed to fit into the entry of the tear duct, releases drug therapy to the surface of the eye over several months.

The therapy may be better than regular eye-drop use, the current standard for treatment, according to a press release.